2023
Jaruthamsophon, K., Thomson, P. J., Hammond, S., Zhang, E., Alfirevic, A., Sukasem, C., . . . Pirmohamed, M. (2023). Characterization of Drug-Specific CD4+T-Cells Reveals Possible Roles of HLA Class II in the Pathogenesis of Carbamazepine Hypersensitivity Reactions. CHEMICAL RESEARCH IN TOXICOLOGY. doi:10.1021/acs.chemrestox.2c00414DOI: 10.1021/acs.chemrestox.2c00414
Developing a warfarin dosing algorithm in patients with mechanical heart valves (Conference Paper)
Zhang, E., Stewart, A., Jorgensen, A., McEvoy, L., Carracedo, A. D., Foster, T., . . . Pirmohamed, M. (2023). Developing a warfarin dosing algorithm in patients with mechanical heart valves. In BRITISH JOURNAL OF CLINICAL PHARMACOLOGY Vol. 89 (pp. 1249-1250). Retrieved from https://www.webofscience.com/
2022
Asiimwe, I. G., Blockman, M., Cohen, K., Cupido, C., Hutchinson, C., Jacobson, B., . . . Pirmohamed, M. (2022). A genome-wide association study of plasma concentrations of warfarin enantiomers and metabolites in sub-Saharan black-African patients.. Frontiers in pharmacology, 13, 967082. doi:10.3389/fphar.2022.967082DOI: 10.3389/fphar.2022.967082
Mone, F., Gupta, J. K., Phelan, M. M., Meher, S., Lian, L. Y., Francis, B., . . . Navaratnam, K. (2022). Platelet response to aspirin in UK and Irish pregnancy cohorts: a genome-wide approach. PLATELETS, 33(6), 911-917. doi:10.1080/09537104.2021.2007872DOI: 10.1080/09537104.2021.2007872
Asiimwe, I. G., Blockman, M., Cohen, K., Cupido, C., Hutchinson, C., Jacobson, B., . . . Pirmohamed, M. (2022). Stable warfarin dose prediction in sub-Saharan African patients: A machine-learning approach and external validation of a clinical dose-initiation algorithm. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 11(1), 20-29. doi:10.1002/psp4.12740DOI: 10.1002/psp4.12740
2021
Bourgeois, S., Carr, D. F., Musumba, C. O., Penrose, A., Esume, C., Morris, A. P., . . . Pirmohamed, M. (2021). Genome-Wide association between EYA1 and Aspirin-induced peptic ulceration. EBioMedicine, 74, 103728. doi:10.1016/j.ebiom.2021.103728DOI: 10.1016/j.ebiom.2021.103728
Systems analysis of miRNA biomarkers to inform drug safety (Journal article)
Schofield, A. L., Brown, J. P., Brown, J., Wilczynska, A., Bell, C., Glaab, W. E., . . . Goldring, C. (2021). Systems analysis of miRNA biomarkers to inform drug safety. ARCHIVES OF TOXICOLOGY, 95(11), 3475-3495. doi:10.1007/s00204-021-03150-9DOI: 10.1007/s00204-021-03150-9
Yates, T., Zaccardi, F., Islam, N., Razieh, C., Gillies, C. L., Lawson, C. A., . . . Khunti, K. (2021). Obesity, Ethnicity, and Risk of Critical Care, Mechanical Ventilation, and Mortality in Patients Admitted to Hospital with COVID-19: Analysis of the ISARIC CCP-UK Cohort. OBESITY, 29(7), 1223-1230. doi:10.1002/oby.23178DOI: 10.1002/oby.23178
Leclerc, Q. J., Fuller, N. M., Keogh, R. H., Diaz-Ordaz, K., Sekula, R., Semple, M. G., . . . Knight, G. M. (2021). Importance of patient bed pathways and length of stay differences in predicting COVID-19 hospital bed occupancy in England. BMC HEALTH SERVICES RESEARCH, 21(1). doi:10.1186/s12913-021-06509-xDOI: 10.1186/s12913-021-06509-x
Asiimwe, I. G., Waitt, C., Sekaggya-Wiltshire, C., Hutchinson, C., Okello, E., Zhang, E. J., . . . Pirmohamed, M. (2021). Developing and Validating a Clinical Warfarin Dose-Initiation Model for Black-African Patients in South Africa and Uganda. CLINICAL PHARMACOLOGY & THERAPEUTICS, 109(6), 1564-1574. doi:10.1002/cpt.2128DOI: 10.1002/cpt.2128
Gupta, R. K., Harrison, E. M., Ho, A., Docherty, A. B., Knight, S. R., van Smeden, M., . . . Noursadeghi, M. (2021). Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. LANCET RESPIRATORY MEDICINE, 9(4), 349-359. doi:10.1016/S2213-2600(20)30559-2DOI: 10.1016/S2213-2600(20)30559-2
Warfarin dosing algorithms: A systematic review (Journal article)
Asiimwe, I. G., Zhang, E. J., Osanlou, R., Jorgensen, A. L., & Pirmohamed, M. (2021). Warfarin dosing algorithms: A systematic review. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(4), 1717-1729. doi:10.1111/bcp.14608DOI: 10.1111/bcp.14608
2020
Thompson, C. P., Grayson, N. E., Paton, R. S., Bolton, J. S., Lourenco, J., Penman, B. S., . . . Simmonds, P. (2020). Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. EUROSURVEILLANCE, 25(42), 33-41. doi:10.2807/1560-7917.ES.2020.25.42.2000685DOI: 10.2807/1560-7917.ES.2020.25.42.2000685
Drake, T. M., Docherty, A. B., Harrison, E. M., Quint, J. K., Adamali, H., Agnew, S., . . . ISARIC4C Investigators. (2020). Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease: An International Multicenter Study.. Am J Respir Crit Care Med. doi:10.1164/rccm.202007-2794OCDOI: 10.1164/rccm.202007-2794OC
Turner, R. M., Fontana, V., Zhang, J. E., Carr, D., Yin, P., FitzGerald, R., . . . Pirmohamed, M. (2020). A Genome‐wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites. Clinical Pharmacology and Therapeutics, 108(2), 287-297. doi:10.1002/cpt.1820DOI: 10.1002/cpt.1820
Asiimwe, I. G., Zhang, E. J., Osanlou, R., Krause, A., Dillon, C., Suarez-Kurtz, G., . . . Pirmohamed, M. (2020). Genetic factors influencing warfarin dose in Black-African patients: a systematic review and meta-analysis.. Clinical Pharmacology and Therapeutics, 107(6), 1420-1433. doi:10.1002/cpt.1755DOI: 10.1002/cpt.1755
Lacaze, P., Ronaldson, K. J., Zhang, E. J., Alfirevic, A., Shah, H., Newman, L., . . . Pirmohamed, M. (2020). Genetic associations with clozapine-induced myocarditis in patients with schizophrenia. TRANSLATIONAL PSYCHIATRY, 10(1). doi:10.1038/s41398-020-0722-0DOI: 10.1038/s41398-020-0722-0
2019
Genomewide Association Study of Statin‐Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink (Journal article)
Carr, D. (2019). Genomewide Association Study of Statin‐Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink. Clinical Pharmacology and Therapeutics, 106(6), 1353-1361. doi:10.1002/cpt.1557DOI: 10.1002/cpt.1557
Danese, E., Raimondi, S., Montagnana, M., Tagetti, A., Langaee, T., Borgiani, P., . . . Fava, C. (2019). The effect of CYP4F2, VKORC1 and CYP2C9 in influencing coumarin dose: A single patient data meta-analysis in more than 15,000 individuals. Clinical pharmacology and therapeutics, 105(6), 1477-1491. doi:10.1002/cpt.1323DOI: 10.1002/cpt.1323
Jorgensen, A. L., Prince, C., Fitzgerald, G., Hanson, A., Downing, J., Reynolds, J., . . . Pirmohamed, M. (2019). Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study. BMC Medicine, 17. doi:10.1186/s12916-019-1308-7DOI: 10.1186/s12916-019-1308-7
Fitzgerald, G., Prince, C., Downing, J., Reynolds, J., Zhang, J. E., Hanson, A., . . . Pirmohamed, M. (2019). Processes and barriers to implementation of point-of-care genotype-guided dosing of warfarin into UK outpatient anticoagulation clinics. PHARMACOGENOMICS, 20(8), 599-608. doi:10.2217/pgs-2019-0021DOI: 10.2217/pgs-2019-0021
2018
Hawcutt, D. B., Francis, B., Carr, D., Jorgensen, A. L., Yin, P., Wallin, N., . . . Pirmohamed, M. (2018). Susceptibility to corticosteroid-induced adrenal suppression: a genome-wide association study. The Lancet Respiratory Medicine, 6(6), 442-450. doi:10.1016/S2213-2600(18)30058-4DOI: 10.1016/S2213-2600(18)30058-4
2017
McCormack, M., Gui, H., Ingason, A., Speed, D., Wright, G. E. B., Zhang, E. J., . . . Rau, S. (2017). Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients. Neurology, 90(4). doi:10.1212/WNL.0000000000004853DOI: 10.1212/WNL.0000000000004853
Zhang, J. E., Klein, K., Jorgensen, A. L., Francis, B., Alfirevic, A., Bourgeois, S., . . . Pirmohamed, M. (2017). Effect of Genetic Variability in the <i>CYP4F2, CYP4F11</i>, and <i>CYP4F12</i> Genes on Liver mRNA Levels and Warfarin Response. FRONTIERS IN PHARMACOLOGY, 8. doi:10.3389/fphar.2017.00323DOI: 10.3389/fphar.2017.00323
Thiesen, S., Yin, P., Jorgensen, A. L., Zhang, J. E., Manzo, V., McEvoy, L., . . . Pirmohamed, M. (2017). <i>TPMT</i>, <i>COMT</i> and <i>ACYP2</i> genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity. PHARMACOGENETICS AND GENOMICS, 27(6), 213-222. doi:10.1097/FPC.0000000000000281DOI: 10.1097/FPC.0000000000000281
2016
Investigating the role of microRNA on warfarin response (Conference Paper)
Zhang, J. E. (n.d.). Investigating the role of microRNA on warfarin response. In Pharmacology 2015. London.
Zhang, J. E. (2016). microRNA: emerging biomarkers in human disease and profiling challenges. Portland Press Ltd.. doi:10.1042/bio03802026DOI: 10.1042/bio03802026
Bourgeois, S., Jorgensen, A., Zhang, E. J., Hanson, A., Gillman, M. S., Bumpstead, S., . . . Pirmohamed, M. (2016). A multi-factorial analysis of response to warfarin in a UK prospective cohort. Genome Medicine: medicine in the post-genomic era, 8. doi:10.1186/s13073-015-0255-yDOI: 10.1186/s13073-015-0255-y
2015
Misoprostol-induced fever and genetic polymorphisms in drug transporters <i>SLCO1B1</i> and <i>ABCC4</i> in women of Latin American and European ancestry (Journal article)
Alfirevic, A., Durocher, J., Elati, A., Leon, W., Dickens, D., Raedisch, S., . . . Winikoff, B. (2015). Misoprostol-induced fever and genetic polymorphisms in drug transporters <i>SLCO1B1</i> and <i>ABCC4</i> in women of Latin American and European ancestry. PHARMACOGENOMICS, 16(9), 919-928. doi:10.2217/pgs.15.53DOI: 10.2217/pgs.15.53
2014
Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects. (Journal article)
Hawcutt, D., Ghani, A., Sutton, L., Jorgensen, A., Zhang, E., Murray, M., . . . Pirmohamed, M. (2014). Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects.. The Pharmacogenomics Journal, 14(6), 542-548. doi:10.1038/tpj.2014.31DOI: 10.1038/tpj.2014.31
Dual Glutathione-<i>S</i>-Transferase-θ1 and -μ1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia (Journal article)
Davies, A., Giannoudis, A., Zhang, J. E., Austin, G., Wang, L., Holyoake, T. L., . . . Clark, R. E. (2014). Dual Glutathione-<i>S</i>-Transferase-θ1 and -μ1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia. CLINICAL PHARMACOLOGY & THERAPEUTICS, 96(6), 694-703. doi:10.1038/clpt.2014.176DOI: 10.1038/clpt.2014.176
Is the Interleukin 8 Promoter Polymorphism rs4073/–251T >A Associated With Clostridium difficile Infection? (Journal article)
Miyajima, F., Swale, A., Zhang, E., Alfirevic, A., Little, M., Beeching, N., . . . Pirmohamed, M. (2014). Is the Interleukin 8 Promoter Polymorphism rs4073/–251T >A Associated With Clostridium difficile Infection?. Clinical Infectious Disease, 58(12), e148-e151. doi:10.1093/cid/ciu152DOI: 10.1093/cid/ciu152
2013
A Randomized Trial of Genotype-Guided Dosing of Warfarin (Journal article)
Pirmohamed, M., Burnside, G., Eriksson, N., Jorgensen, A. L., Toh, C. H., Nicholson, T., . . . Wadelius, M. (2013). A Randomized Trial of Genotype-Guided Dosing of Warfarin. NEW ENGLAND JOURNAL OF MEDICINE, 369(24), 2294-2303. doi:10.1056/NEJMoa1311386DOI: 10.1056/NEJMoa1311386
A Randomized Trial of Genotype-Guided Dosing of Warfarin (Journal article)
Pirmohamed, M., Burnside, G., Eriksson, N., Jorgensen, A. L., Toh, C. H., Nicholson, T., . . . Wadelius, M. (2013). A Randomized Trial of Genotype-Guided Dosing of Warfarin. New England Journal of Medicine, 369(24), 2294-2303. doi:10.1056/nejmoa1311386DOI: 10.1056/nejmoa1311386
<i>CYP2C19*17</i> Gain-of-Function Polymorphism Is Associated With Peptic Ulcer Disease (Journal article)
Musumba, C. O., Jorgensen, A., Sutton, L., Van Eker, D., Zhang, E., O'Hara, N., . . . Pirmohamed, M. (2013). <i>CYP2C19*17</i> Gain-of-Function Polymorphism Is Associated With Peptic Ulcer Disease. CLINICAL PHARMACOLOGY & THERAPEUTICS, 93(2), 195-203. doi:10.1038/clpt.2012.215DOI: 10.1038/clpt.2012.215
The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia (Journal article)
Giannoudis, A., Wang, L., Jorgensen, A. L., Xinarianos, G., Davies, A., Pushpakom, S., . . . Clark, R. E. (2013). The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. BLOOD, 121(4), 628-637. doi:10.1182/blood-2012-01-405035DOI: 10.1182/blood-2012-01-405035
The hOCT1 single nucleotide polymorphisms M420del and M408V alter imatinib uptake and modify clinical outcome in imatinib treated chronic myeloid leukaemia (Journal article)
Giannoudis, A., Wang, L., Jorgensen, A. L., Xinarianos, G., Davies, A., Pushpakom, S., . . . Clark, R. E. (2013). The hOCT1 single nucleotide polymorphisms M420del and M408V alter imatinib uptake and modify clinical outcome in imatinib treated chronic myeloid leukaemia. Blood, 121, 628-637.
2012
Impact of the <i>CYP4F2</i> p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta-Analysis (Journal article)
Danese, E., Montagnana, M., Johnson, J. A., Rettie, A. E., Zambon, C. F., Lubitz, S. A., . . . Fava, C. (2012). Impact of the <i>CYP4F2</i> p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta-Analysis. CLINICAL PHARMACOLOGY & THERAPEUTICS, 92(6), 746-756. doi:10.1038/clpt.2012.184DOI: 10.1038/clpt.2012.184
CYP2C19*17 GAIN OF FUNCTION MUTATION IS ASSOCIATED WITH PEPTIC ULCER DISEASE (Journal article)
Musumba, C. O., Eker, D. V., Jorgensen, A., Pritchard, D. M., & Pirmohamed, M. (2012). CYP2C19*17 GAIN OF FUNCTION MUTATION IS ASSOCIATED WITH PEPTIC ULCER DISEASE. GUT, 61, A363. doi:10.1136/gutjnl-2012-302514d.165DOI: 10.1136/gutjnl-2012-302514d.165
2009
Effects of <i>CYP4F2</i> genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy (Journal article)
Zhang, J. E., Jorgensen, A. L., Alfirevic, A., Williamson, P. R., Toh, C. H., Park, B. K., & Pirmohamed, M. (2009). Effects of <i>CYP4F2</i> genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. PHARMACOGENETICS AND GENOMICS, 19(10), 781-789. doi:10.1097/FPC.0b013e3283311347DOI: 10.1097/FPC.0b013e3283311347
Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study (Journal article)
Jorgensen, A. L., Al-Zubiedi, S., Zhang, J. E., Keniry, A., Hanson, A., Hughes, D. A., . . . Pirmohamed, M. (2009). Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. PHARMACOGENETICS AND GENOMICS, 19(10), 800-812. doi:10.1097/FPC.0b013e3283317ab5DOI: 10.1097/FPC.0b013e3283317ab5
EFFECTS OF CYP4F2 GENETIC POLYMORPHISMS AND HAPLOTYPES ON CLINICAL OUTCOMES IN PATIENTS INITIATED ON WARFARIN THERAPY (Journal article)
Zhang, J. E., Jorgensen, A. L., Alfirevica, A., Williamson, P. R., Toh, C. H., Park, B. K., & Pirmohamed, M. (2009). EFFECTS OF CYP4F2 GENETIC POLYMORPHISMS AND HAPLOTYPES ON CLINICAL OUTCOMES IN PATIENTS INITIATED ON WARFARIN THERAPY. Pharmacogenetics and Genomics, (19), 781-789.
